Scandion Oncology

Scandion is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has shown to improve the effect of certain standard cancer treatments during preclinical studies. The head office of the company is located in Copenhagen.

Quotes for Scandion Oncology

Right Now

+/-
%
Latest
High
Low
Volume
Turnover ()
Time (Latest trade)

Board

CEO

  • Bo Rode Hansen

Chairperson of the Board

  • Peter Høngaard

Board

  • Annie Rasmussen
  • Bo Hansen
  • Carl Borrebäck
  • Christian Vinding Thomsen
  • Jørgen Bardenfleth
  • Thomas Feldthus
  • Articles of association

    • News

    Show More

    Analysis

    Videos

    Presentation av Scandion Oncology A/S med CEO Bo Rode Hansen hos Nordnet Danmark (EN).

    Scandion Oncology’s CEO comments on ongoing rights issue

    Company Presentation

    Largest Owners

    Name Capital % Votes % Date
    Dan Peters 19,69 19,69 2025-10-29
    Sören Kölle Christensen 3,55 3,55 2025-10-29
    Avanza Pension 2,90 2,90 2025-10-29
    Indraj Kumar Shikar Puri 2,19 2,19 2025-10-29
    Sparekassen Kronjylland - General Client Account 1,81 1,81 2025-10-29
    Thomas Khanu 1,74 1,74 2025-10-29
    Che Harald Mårten Vågerö 1,58 1,58 2025-10-29
    Yan Xiong 1,37 1,37 2025-10-29
    Johan Haag 1,30 1,30 2025-10-29
    Rossen Denmark Aps 1,19 1,19 2025-10-29

    Annual reports, prospectus etc.